October 28, 2022 — Heart Test Laboratories, Inc., a medical technology company focused on saving lives by making an ECG (also known as an EKG) a far more valuable screening tool through the use of AI, announced it has been granted a patent from the European Patent Office (EPO). The patent covers the design of the Company’s electrode and cable connectors for use with an ECG, and in particular its MyoVista device.
“Millions of ECGs are performed every week. The electrodes used with the MyoVista are proprietary to HeartSciences. Adding Europe to our electrode patent coverage strengthens and diversifies our overall intellectual property portfolio as well as further protects future recurring revenues. This granted patent enhances our strategic position as we progress toward commercialization,” stated Andrew Simpson, CEO of HeartSciences.
“Unlike a conventional ECG, the MyoVista AI algorithm for cardiac dysfunction analyzes frequency signals from the heart. Our unique electrode design helps ensure an optimal, high quality, low impedance signal capture for each and every test. We have secured a number of U.S. and international patents and this most recent expansion of our IP portfolio is an example of how we continue to leverage our first mover advantage as we position ourselves to deliver a new era of clinical value for ECGs across the US and internationally.”
Electrocardiography (ECG) systems analyze the electrical activity of the heart by recording and processing electrical signals using electrodes placed on a patient’s body. The MyoVista 12-lead AI-enabled ECG system includes electrodes and a processing device connected to the electrodes via a suitable cable. For safety and security, new electrodes are used for every ECG test.
For more information: https://www.heartsciences.com